One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2020-134602
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2020 |
 Citations: 3 |
Affiliation: Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Centre Hospitalier Universitaire de Nice, Hôpital Cardiologique du Haut-Lévêque, University of Rochester, Oregon Health & Science University, Centre Hospitalier de Versailles, Duke University, Hôpital Avicenne, University of Michigan–Ann Arbor, Cornell University, NewYork–Presbyterian Hospital, New York Hospital Queens, Presbyterian Hospital, Centre Hospitalier Universitaire Amiens-Picardie
Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
